Transplantation and Cellular Therapy | 2025
Donor type does not impact late graft failure following reduced-intensity allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.
Hickey CL, Zhang M, Allbee-Johnson M, Romee R, Majhail NS, Malki M, Antin JH, Benjamin CL, Bredeson C, Chhabra S, Grunwald MR, Inamoto Y, Kanakry CG, Milano F, Soiffer RJ, Spellman SR, Solomon SR, Brunstein CG, Cutler C
PubMed
PMID: 39755256
Abstract
Related Articles
CIBMTR Study #: GS19-02